Cutting-edge wearable technology pulling cancer patients out of death lists – Smartwatch Blog


A new trial, dedicated to testing cutting-edge wearable technologies involving patients who have received cancer treatment, opened in Greater Manchester recently.

A digital fingerprint of vital signs produced by the commercially-available health sensors and devices allows doctors to assess the progress of their patients. The trial is called EMBRaCE (Enhanced Monitoring for Better Recovery and Cancer Experience), which is a collaboration between Manchester University NHS Foundation Trust, The Christie NHS Foundation Trust, and The University of Manchester.

The trial opens initially for blood cancer, lung, and colorectal cancer patients and will run across Greater Manchester.

The technologies under investigation include:

  • a smart ring, worn on any finger made by the company Oura
  • the Withings ScanWatch, a hybrid smartwatch
  • the Isansys system, which is worn on the chest

These cutting-edge technologies will provide 24/7 data, which might lead to new insights into how people cope with cancer treatment and what doctors can improve their recovery.

This trial will assess if the latest wearable technology has a role in cancer care, then help doctors to identify ways that clinical staff can individualize treatment before, during, and after therapy.

“We will find out if 24/7 data from these wearable sensors can be used to support patient recovery and provide accurate measurement outside the clinic. It could even support the development of new cancer treatments by developing a digital platform for clinical trials in cancer involving wearable devices or fitness trackers,” Dr. Michael Merchant said, the Senior Lecturer in Proton Therapy Physics, at The University of Manchester.

As a matter of fact that the trial actually was not designed to cure cancer. Steve McConchie, CEO of Aptus Clinical, a clinical contract research organization based in Alderley Park, Cheshire, said: “We are delighted that the clinical data collection and curation infrastructure we initially created to support an important piece of exploratory research into COVID-19 is being expanded to assess the utility of patient wearables to improve the care of cancer patients across Manchester.”



Source link

We will be happy to hear your thoughts

Leave a reply

MB DROPS
Logo
Enable registration in settings - general
Shopping cart